# A Phase IB Study to Determine the Safety and Tolerability of Canakinumab and Tislelizumab in Combination With Nab-Paclitaxel and Gemcitabine in the Neo-adjuvant Treatment of Patients With Pancreatic Cancer

> **NCT05984602** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **NYU Langone Health** · enrollment: 9 (actual)

## Conditions studied

- Pancreatic Cancer

## Interventions

- **DRUG:** Canakinumab
- **DRUG:** Tislelizumab
- **DRUG:** Nab-Paclitaxel
- **DRUG:** Gemcitabine

## Key facts

- **NCT ID:** NCT05984602
- **Lead sponsor:** NYU Langone Health
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-07-14
- **Primary completion:** 2025-09-01
- **Final completion:** 2026-07-01
- **Target enrollment:** 9 (ACTUAL)
- **Last updated:** 2026-03-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05984602

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05984602, "A Phase IB Study to Determine the Safety and Tolerability of Canakinumab and Tislelizumab in Combination With Nab-Paclitaxel and Gemcitabine in the Neo-adjuvant Treatment of Patients With Pancreatic Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05984602. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*